CLINICAL_TRIALS
trial_result
· 2017-07-18
Clinical Trial Update: A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis [Phase 2]
Summary
Phase 2b study of baricitinib in moderate to severe psoriasis completed, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Psoriasis, Skin Diseases | Phase 2 | Status: COMPLETED | Results posted: 2017-07-18